Deborah Cho

Deborah's practice includes assisting clients with lifecycle management and product development and approval.  She has deep experience with the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act, both from her time in private practice and at the FDA.  

Deborah began her legal career in the FDA’s Office of Chief Counsel. As Associate Chief Counsel for Drugs, Deborah counseled FDA’s Center for Drug Evaluation and Research (CDER) on generic drugs, biosimilars, and pediatric drug development.  Deborah also advised FDA’s Office of Good Clinical Practice on matters related to human subject protection in clinical investigations.  During her tenure at the FDA, she received FDA and CDER Group Recognition Awards for the review of the first biosimilar approved for the treatment of cancer, the Office of the Chief Counsel Biosimilars Team, and the MMA Rule (2016 Hatch-Waxman regulations) Working Group.

Prior to joining Hogan Lovells, Deborah was an associate at another international law firm, where she counseled clients on FDA regulatory issues and routinely provided regulatory support for corporate transactions and securities offerings involving drugs, biological products, medical devices, and foods.  

Deborah received her J.D. from Harvard Law School and has a background in biochemistry and bioethics. While in law school, she worked as an intern for the HHS Office of the General Counsel in the Centers for Medicare and Medicaid Services (CMS) Division as well as the Centers for Disease Control and Prevention (CDC) Branch.